Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With <i>ERBB2/HER2</i>-Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial

Gianni, Luca; Mansutti, M.; Antón, Antonio; Calvo, Lourdes; Bisagni, Giancarlo; Bermejo, Begoña; Семиглазов, Владимир; Thill, Marc; Chacón, José Ignacio; Chan, Arlene; Morales, Serafín; Álvarez-López, Isabel; Plazaola, Arrate; Zambetti, Milvia; Redfern, Andrew; Dittrich, Christian; Dent, Rebecca; Magazzù, Domenico; Fato, Raffaella De; Valagussa, Pinuccia; Tusquets, Ignacio

doi:10.1001/jamaoncol.2017.4612

Cited by 123 publications

(106 citation statements)

References 15 publications

Supporting

Mentioning

100

Contrasting

Unclassified

Order By: Relevance

“…Conversely, in the phase III ETNA trial conducted in 695 patients with HER2 negative early or locally advanced BC, a slight and not statistically significant improvement in pCR rate was registered in the nab-paclitaxel arm compared to paclitaxel cohort (22% vs. 19%), even in patients with TNBC (41% vs. 37%) [88]. Likewise, the secondary endpoint of 5-year event free survival (EFS) was not statistically different between neoadjuvant nab-paclitaxel compared to standard paclitaxel [89].…”

Section: Taxanesmentioning

confidence: 86%

Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes

Diana

Carlino

Franzese

et al. 2020

Cancers

View full text Add to dashboard Cite

Triple negative breast cancers (TNBCs) are characterized by worse prognosis, higher propensity to earlier metastases, and shorter survival after recurrence compared with other breast cancer subtypes. Anthracycline- and taxane-based chemotherapy is still the mainstay of treatment in early stages, although several escalation approaches have been evaluated to improve survival outcomes. The addition of platinum salts to standard neoadjuvant chemotherapy (NACT) remains controversial due to the lack of clear survival advantage, and the use of adjuvant capecitabine represents a valid treatment option in TNBC patients with residual disease after NACT. Recently, several clinical trials showed promising results through the use of poly ADP-ribose polymerase (PARP) inhibitors and by incorporating immunotherapy with chemotherapy, enriching treatment options beyond conventional cytotoxic agents. In this review, we provided an overview on the current standard of care and a comprehensive update of the recent advances in the management of early stage TNBC and focused on the latest emerging biomarkers and their clinical application to select the best therapeutic strategy in this hard-to-treat population.

show abstract

Section: Taxanesmentioning

confidence: 86%

Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes

Diana

Carlino

Franzese

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…Conventional sb‐taxanes (such as paclitaxel and docetaxel) destabilize the microtubules and hence prevent cell proliferation, and are among the most widely used chemotherapies . Because taxanes are poorly soluble in water‐based solutions, polyethylated castor oil and ethanol are needed in sub‐taxane preparations to increase the taxanes' solubility . Therefore, premedication and long infusion times are necessary to avoid hypersensitivity reactions .…”

Section: Discussionmentioning

confidence: 99%

“…Because taxanes are poorly soluble in water‐based solutions, polyethylated castor oil and ethanol are needed in sub‐taxane preparations to increase the taxanes' solubility . Therefore, premedication and long infusion times are necessary to avoid hypersensitivity reactions . In addition, the paclitaxel is trapped in micelles by the cremophor excipient, resulting in nonlinear pharmacokinetics .…”

Section: Discussionmentioning

confidence: 99%

Retrospective analysis of the effectiveness and tolerability of nab‐paclitaxel in Chinese elderly patients with advanced non‐small‐cell lung carcinoma

et al. 2020

View full text Add to dashboard Cite

Background: Previous trials have suggested that elderly patients with non-small-cell lung cancer (NSCLC) could benefit from nanoparticle albumin-bound paclitaxel (nab-paclitaxel). Real-world data on the elderly Chinese population are lacking. This study aimed to analyze the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients (≥65 years) with advanced NSCLC. Methods: This study included 76 patients with a primary diagnosis of IIIB-IV NSCLC from January 2010 to December 2017 at Peking University Cancer Hospital, who received nab-paclitaxel (125 or 130 mg/m 2 i.v.) every three weeks. The overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs) were analyzed. Results: There were 12 patients who received nab-paclitaxel as the first-line treatment (seven also received carboplatin), and 64 received nab-paclitaxel as the latter-line treatment. The overall ORR, DCR, median PFS, and median OS were 14.5%, 69.7%, 5.2 months, and 12.2 months, respectively. The Eastern Cooperative Oncology Group performance status of one and the age of 70-74 years were independently associated with longer OS, while early treatment line of nabpaclitaxel and age of 70-74 years were independently associated with longer PFS. The most common AEs were anemia, leukopenia, gastrointestinal reaction, fatigue, and peripheral neuropathy, which were all manageable. Dose adjustment or treatment discontinuation was encountered in 10 patients because of AEs. The incidence of AEs was not different among age subgroups. Conclusions: Nab-paclitaxel has a good clinical response profile in Chinese elderly patients with stage IIIB-IV NSCLC. Prospective clinical trials are needed to confirm these results. Key pointsSignificant findings of the study: Nanoparticle albumin-bound paclitaxel (nabpaclitaxel) has a good clinical response profile in Chinese elderly (≥65 years) patients with stage IIIB-IV non-small-cell lung cancer (NSCLC), with acceptable and manageable adverse events. What this study adds: Preliminary evidence shows a good clinical response from treatment with nab-paclitaxel in Chinese elderly patients with advanced NSCLC.

show abstract

“…В исследовании III фазы ETNA [15] не получено достоверных различий в эффективности применения набпаклитаксела и стандартной формы паклитаксела в неоадъювантных режимах (22,5% против 18,6% соответственно, ОР-0,77; 95% ДИ 0,52-1,13; P = 0,19). Однако еще раз продемонстрировано, что наилучший выигрыш в достижении полной морфологической регрессии имеют больные ТН РМЖ: 41,3% против 8,2% при люминальном-В подтипе в группе терапии наб-паклитакселом.…”

Section: набпаклитаксел в неоадъювантной химиотерапии рака молочной unclassified

The prospects for cisplatin and nab-paclitaxel combination therapy in patients with pre-treated triple-negative breast cancer. Description of the clinical case.

Жукова¹,

Bardovskaya²,

Lubennikova³

et al. 2018

Med. sov.

View full text Add to dashboard Cite

ГБУЗ «Московский клинический научный центр им. А.С. Логинова» Департамента здравоохранения г. Москвы 2 ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России, Москва 3 ГБУЗ «Онкологический диспансер №4 Департамента здравоохранения г. Москвы» ВОЗМОЖНОСТИ ТЕРАПИИ БОЛЬНЫХ С ПРЕДЛЕЧЕННЫМ ТРИЖДЫ НЕГАТИВНЫМ РАКОМ МОЛОЧНОЙ ЖЕЛЕЗЫ КОМБИНАЦИЕЙ ЦИСПЛАТИНА И НАБ-ПАКЛИТАКСЕЛА ОПИСАНИЕ КЛИНИЧЕСКОГО СЛУЧАЯМолекулярно-биологические особенности трижды негативного рака молочной железы (ТН РМЖ) определяют ограниченные возможности системной терапии и, как следствие, более агрессивное течение болезни. Среди химиопрепаратов, используемых в терапии РМЖ, таксаны являются одними из наиболее эффективных. Особая форма паклитаксела -набпаклитаксел -позволяет получить объективный и, что особенно важно у предлеченных больных, субъективный эффект, при этом препарат имеет благоприятный профиль безопасности и хорошо управляемую токсичность. В статье представлен обзор литературы о перспективах применения наб-паклитаксела при РМЖ, особенно при его трижды негативном варианте, а также приведено описание клинического случая терапии комбинацией цисплатина и набпаклитаксела у молодой больной с BRCA-1-ассоциированным ТН РМЖ. Ключевые слова: трижды негативный рак молочной железы, таксаны, наб-паклитаксел. . Molecular and biological features of triple negative breast cancer (TN BC) determine the limited possibilities of systemic therapy and, as a consequence, the more aggressive course of the disease. Taxanes are one of the most effective chemotherapies used in breast cancer therapy. The special form of paclitaxel -nab-paclitaxel -makes it possible to obtain an objective and a subjective effect, which is especially important in the pre-treated patients. In addition, the drug has a favourable safety profile and a well-controlled toxicity. The article contains a review of the literature on the prospects for the use of nab-paclitaxel in breast cancer, especially in its triple negative version, and a description of the clinical case of therapy with a combination of cisplatin and nab-paclitaxel in a young patient with BRCA-1-associated TN breast cancer.

show abstract

Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial

Abstract: clinicaltrials.gov Identifier: NCT01822314.

Cited by 123 publications

References 15 publications

Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes

Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes

Retrospective analysis of the effectiveness and tolerability of nab‐paclitaxel in Chinese elderly patients with advanced non‐small‐cell lung carcinoma

The prospects for cisplatin and nab-paclitaxel combination therapy in patients with pre-treated triple-negative breast cancer. Description of the clinical case.

Contact Info

Product

Resources

About